Sinovac Gets Anflu Boost

Shares climb on news its third product, an influenza vaccine, is now for sale in China.
Publish date:

Shares of

Sinovac Biotech

(SVA) - Get Report

got a boost Wednesday on news the China-based company's third product, a seasonal influenza vaccine, has been released for sale in China.

The day the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) released Anflu for sale, Sinovac signed several purchase orders, the company said.

The premarket news sent shares of the biopharmaceutical company, which focuses on vaccines that protect against human infectious diseases, higher. After closing Tuesday at $2.65, the stock opened Wednesday 10 cents higher and is now trading up another 11% , or 29 cents, at $2.94.